Tovetumab Biosimilar - Research Grade

Human

PDGFR alpha

>1mg/ml

Human IgG2-Kappa

Olaratumab Biosimilar - Research Grade (ICH5305)

https://www.imgt.org/mAb-DB/

ICH3002

P16234

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of tovetumab, supplied strictly for research use. It is built as a human IgG2-kappa antibody directed against human platelet-derived growth factor receptor alpha (PDGFR alpha / PDGFRA, UniProt P16234), reproducing the target specificity of the originator molecule without being the clinical drug and without any conjugation. It is not intended for human or veterinary use. Because it recapitulates receptor binding, it is useful as a defined tool for interrogating PDGFR alpha signaling: as a binding and ligand-blocking reagent, an isotype-matched or receptor-specific control, a positive control in receptor-detection assays, and a starting reagent for ADCC or antibody-drug-conjugate development workflows. It is offered at research-grade low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option), and in bulk milligram-to-gram quantities suitable for repeated in-vitro experiments, assay standardization, and preclinical model work. Lot-to-lot consistency and defined formulation make it appropriate for comparative and quantitative studies where a reproducible anti-PDGFR alpha reagent is required. PDGFR alpha (PDGFRA) is a type III receptor tyrosine kinase with five extracellular immunoglobulin-like domains, a single transmembrane segment, and a split intracellular kinase domain. It binds PDGF ligands (PDGF-AA, -AB, -BB, and -CC), which drives receptor dimerization, autophosphorylation, and recruitment of effectors including PI3K/AKT, RAS/MAPK, PLC-gamma, and STATs. Signaling regulates proliferation, survival, migration, and mesenchymal cell development, and is important in fibroblast, pericyte, and connective-tissue biology as well as gastrulation and organ development. Dysregulated PDGFRA activity, through activating mutations, gene amplification, or fusion events, contributes to gastrointestinal stromal tumors, gliomas, and certain eosinophilic disorders (FIP1L1-PDGFRA). It also mediates paracrine and autocrine loops in the tumor microenvironment. These features make PDGFR alpha a well-characterized target for receptor-blocking and signaling studies.

CD140a

Detects human PDGFR alpha

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.